Key Highlights

  • Gildan Activewear (NYSE:GIL) cut its 2026 adjusted EPS range to USD 3.70 to USD 3.80, against a previous USD 4.65 to USD 4.75, and intraday quotes put the stock 22.53% lower.
  • Molson Coors Beverage (NYSE:TAP) projects 2026 underlying EPS to fall 16% to 19%, a steeper drop than the 11% to 15% decline it had previously guided.
  • Himax Technologies (NASDAQ:HIMX) guided fourth-quarter Revenue 22% to 26% below the third quarter, and a single listing showed its shares down 26.44%.
  • Third-quarter revenue at Veracyte (NASDAQ:VCYT) rose 15% to USD 151.8 million, while one listing put its shares 54.30% lower after the testing revenue range was trimmed.

Gildan Activewear (NYSE:GIL): Sales Land Below the Company's Own Forecast

Gildan Activewear (NYSE:GIL) released its third-quarter numbers on November 5, 2026. Net sales from continuing operations hit USD 1.47 billion, a 61.1% rise, but they came in roughly USD 180 million, or about 11%, short of the company's own forecast of about USD 1.65 billion (calculated). Adjusted diluted Earnings reached USD 1.54 per share, up 54.0%, and the quarter generated USD 606 million of free cash flow. Market data placed the stock 22.53% lower intraday, though no closing price has been confirmed. Full-year adjusted EPS is now seen at USD 3.70 to USD 3.80, roughly 20% under the old midpoint (calculated), while net sales are projected at USD 5.4 billion to USD 5.5 billion. Gildan also dropped its 2026 to 2028 targets, and its normal course issuer bid was renewed starting November 9, 2026, which permits buying back as many as 9,260,156 shares. That number marks a maximum, not a pledge. Softer retail restocking and weaker pricing are the chief hazards.

Molson Coors Beverage (NYSE:TAP): Lower Volume and Aluminum Costs Push the Decline Deeper

Molson Coors Beverage (NYSE:TAP) reported third-quarter earnings on November 5, 2026, and now projects that 2026 underlying EPS will decline 16% to 19%, steeper than the 11% to 15% it had guided before. Net sales eased 1.6% to USD 2,926.5 million, financial volume shrank 3.0% and Brand volume contracted 4.9%, with the U.S. recording a 5.6% drop. Underlying EBITDA landed at USD 592.1 million compared with USD 665.4 million a year earlier, about 11.0% lower (calculated). Costs for Midwest Premium aluminum added roughly USD 30 million this quarter and should run about USD 130 million above 2025 across the year. Net Debt reached USD 5,393.6 million, equal to 2.53 times underlying EBITDA against 2.28 times previously. The quarterly Dividend rose to USD 0.48 a share from USD 0.47. A market review asserted that sales and adjusted earnings fell short of estimates without offering figures, so the scale of any shortfall is unconfirmed, and no verified share price reaction has surfaced.

Himax Technologies (NASDAQ:HIMX): Automotive Order Cuts Overshadow an Earnings Beat

Himax Technologies (NASDAQ:HIMX) posted third-quarter results on November 5, 2026, and steered fourth-quarter revenue 22% to 26% lower than the third quarter, a band of about USD 183 million to USD 193 million measured against USD 246.8 million (calculated). Management attributed the slide to sudden, short-lived order revisions from some customers buying automotive driver chips, together with Chinese automakers' overly ambitious export outlooks and inventory sitting in channels. The quarter itself was respectable: revenue climbed 8.5% from the prior quarter, gross Margin widened to 34.2% from 33.1%, and profit of 10.7 cents per diluted ADS beat the 8.0 to 10.0 cent guidance. Fourth-quarter profit is pointed to at 4.5 to 6.5 cents per diluted ADS, which excludes a possible gain from a proposed divestiture not yet reviewed and sits roughly 39% to 58% below the third quarter (calculated). One listing with unclear labels showed the shares 26.44% lower in the regular session, following a premarket fall of about 24%. Himax makes display driver and image processing chips, and each ADS stands for two ordinary shares. Cash totaled USD 285.3 million at September 30, 2026, against USD 298.7 million three months before, and when automotive orders will normalize is anyone's guess.

Veracyte (NASDAQ:VCYT): Revenue Rises 15% as the Testing Range Narrows

Veracyte (NASDAQ:VCYT) issued its third-quarter report on November 4, 2026. Published market data recorded a 54.30% regular-session decline on November 5, yet that figure traces back to one listing and has not been independently verified. Total revenue advanced 15%, reaching USD 151.8 million against USD 131.9 million a year earlier, while testing revenue increased 15% to USD 146.4 million, and Net Income came to USD 31.5 million alongside adjusted EBITDA of USD 41.2 million. Management reduced the 2026 testing revenue band to USD 571 million to USD 573 million, down from a prior USD 576 million to USD 582 million, a USD 7 million cut at the midpoint (calculated). Total revenue guidance now spans USD 590 million to USD 593 million, versus USD 590 million to USD 596 million before. The company builds genomic tests that guide cancer treatment decisions. Decipher Prostate, its flagship line, booked USD 92.3 million from roughly 29,900 tests, a 12% rise that trailed the company's 15% overall pace. A market wrap called preliminary 2027 guidance far below consensus and mentioned a research firm downgrade, but the company release included no 2027 numbers, so neither claim is confirmed. Cash and short-term investments stood at USD 370.5 million, while slower test uptake and payer coverage rulings remain the main threats.

Where Things Stand

Only partly. The four names share a reset in expectations, yet the triggers and the reported reactions diverge. Gildan Activewear (NYSE:GIL) fell short of its own sales forecast and abandoned multi-year targets. Molson Coors Beverage (NYSE:TAP) deepened its guided earnings decline because of volume and aluminum, with no verified share reaction. Himax Technologies (NASDAQ:HIMX) cleared its own profit bar but signaled a sequential revenue drop of 22% to 26%. Its testing band lost about USD 7 million at the midpoint (calculated), and a reported 54.30% fall would point to a wider rethink of growth at Veracyte (NASDAQ:VCYT). The Gildan, Himax and Veracyte share moves each come from single listings and are not confirmed closes. Nothing in this group is a recommendation. Watch Gildan's buyback restart on November 9 and the fourth-quarter reports that follow.